封面
市場調查報告書
商品編碼
1087059

黑色素瘤治療:市場預測(2022年~2027年)

Melanoma Treatment Market - Forecasts from 2022 to 2027

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球黑色素瘤治療的市場規模預測將從2020年的35億8,600萬美金,在預測期間內預計將以15.12%的年複合成長率擴大,到2027年達到96億800萬美元。

本報告提供黑色素瘤治療的世界市場調查,提供市場規模和預測,市場促進因素及課題,市場趨勢,各市場區隔的市場分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 假設

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商者的威脅
    • 競爭企業間的敵對關係
  • 產業的價值鏈分析

第5章 黑色素瘤治療市場:各類型

  • 皮膚黑色素瘤
  • 眼內黑色素瘤
  • 粘膜黑色素瘤

第6章 黑色素瘤治療市場:不同治療

  • 手術
  • 免疫療法
  • 標靶治療
  • 化療
  • 放射治療

第7章 黑色素瘤治療市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 日本
    • 其他

第8章 競爭情形與分析

  • 主要企業策略分析
  • 新興企業與市場的有利性
  • 合併,收購,協定,及合作
  • 供應商競爭力矩陣

第9章 企業簡介

  • Merck & Co. Inc.
  • Amgen Inc.
  • Iovance Biotherapeutics, Inc,
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche Ltd
  • Eisai Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • AstraZeneca
簡介目錄
Product Code: KSI061610401

The melanoma treatment market is projected to witness a CAGR of 15.12% during the forecast period to reach a market size of US$9.608 billion by 2027, increasing from US$3.586 billion in 2020.

Introduction.

In recent years, there has been a rise in the number of new cases reported due to climatic changes. These changes are increasing the incidence of melanoma patients worldwide, raising the demand for proper methods of treatment. If detected and treated early, the disease is almost always curable. The rising per capita income, better health facilities, growing health awareness, the availability of health insurance services, and advancement in medical science and bio-medicines are additionally factoring in the expansion of the market.

Geographically, North America dominates the market share. The high prevalence of skin-related cancer in the United States is a major factor contributing to the market's growth. By type, cutaneous melanoma is widely spread globally caused by too much exposure to ultraviolet rays from the sun and indoor tanning. Based on therapy, targeted therapy is gaining the market share due to lesser side effects and high efficiency rates.

Growth Factors.

  • Growing regulatory approvals.

The high emphasis and consequently the elevated investment in the development of efficient treatment options are likely to have a positive impact on the growth of the market. Treatment recommendations depend on many factors, and the increasing number of regulatory approvals has made the highest impact on market growth. In 2021, Aldesleukin, Binimetinib, Braftovi (Encorafenib), Cobimetinib Fumarate, Cotellic (Cobimetinib Fumarate), Dabrafenib Mesylate, etc. were some of the approved drugs for the treatment by FDA. The emphasis of significant companies on introducing innovative treatment options and drugs will aid the market's growth in the coming years.

Impact of COVID-19 on the Melanoma Treatment Market

The pandemic has had a lagging effect on various diagnostic methods due to several restrictions and risk exposure of the comorbidity patients. A drastic reduction in skin biopsies was seen early in the COVID-19 pandemic, which disproportionately affected the elderly, females, and certain geographic regions. Efforts have been made by the government to contain the situation without further delay.

Competitive Insights.

The market leaders for the melanoma treatment market are Merck & Co. Inc., Amgen Inc., Iovance Biotherapeutics, Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd., Novartis AG, Pfizer Inc., Sanofi, and AstraZeneca.

  • In 2021, Oncosec Medical Inc. and Merck and Co. collaborated to study phase III metastatic melanoma.
  • In 2021, Amgen completed the acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share and is set to acquire Teneobio, a privately held, clinical-stage biotechnology company.
  • In 2020, Iovance Biotherapeutics, Inc sold $500 million of its common stock, subject to market and other conditions, in an underwritten public offering. In 2021, there has been certain turmoil, and the company is looking for buy-out options.
  • In 2019, Bristol-Myers Squibb Company and Celgene Corporation entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene for approximately $74 billion to create an innovative biopharma company.
  • In 2020, Novartis AG acquired The Medicines Company, and in 2018 GlaxoSmithKline plc reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion.
  • In 2020, FDA approved AstraZeneca and Merck & Co.'s drug selumetinib to treat neurofibromatosis type 1, or NF1, a rare and typically inherited disease that causes tumors to grow inside nerve sheaths. Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.

Segmentation:

  • By Type

Cutaneous Melanoma

Ocular Melanoma

Mucosal Melanoma

  • By Therapy

Surgery

Immunotherapy

Targeted Therapy

Chemotherapy

Radiation Therapy

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • Germany
  • France
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Powers of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. The Threat of New Entrants
    • 4.3.5. Competitive Rivalry in Industry
  • 4.4. Industry Value Chain Analysis

5. MELANOMA TREATMENT MARKET BY TYPE

  • 5.1. Cutaneous Melanoma
  • 5.2. Ocular Melanoma
  • 5.3. Mucosal Melanoma

6. MELANOMA TREATMENT MARKET BY THERAPY

  • 6.1. Surgery
  • 6.2. Immunotherapy
  • 6.3. Targeted Therapy
  • 6.4. Chemotherapy
  • 6.5. Radiation Therapy

7. MELANOMA TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom 
    • 7.4.4. Spain 
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Israel
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. South Korea
    • 7.6.4. Taiwan
    • 7.6.5. Thailand
    • 7.6.6. Indonesia 
    • 7.6.7. Japan
    • 7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrative
  • 8.3. Mergers, Acquisition, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Merck & Co. Inc.
  • 9.2. Amgen Inc.
  • 9.3. Iovance Biotherapeutics, Inc,
  • 9.4. Bristol-Myers Squibb 
  • 9.5. F. Hoffmann-La Roche Ltd
  • 9.6. Eisai Co., Ltd.
  • 9.7. Novartis AG
  • 9.8. Pfizer Inc.
  • 9.9. Sanofi
  • 9.10. AstraZeneca